Skip to main content
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. — Investor Relations & Filings

Ticker · PTHS ISIN · US1711261057 US Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2025-11-07 Regulatory Filings
Country US United States of America
Listing US PTHS

About Pelthos Therapeutics Inc.

https://ir.pelthos.com/

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for patients with unmet medical needs. Its lead product is ZELSUVMI™ (berdazimer topical gel, 10.3%), the first FDA-approved, at-home prescription treatment for molluscum contagiosum. ZELSUVMI is based on the company's proprietary nitric oxide-releasing technology platform, NITRICIL™, which is also being utilized for a pipeline of other product candidates. The company's portfolio also includes the acquired asset Xepi (ozenoxacin) Cream, 1%.

Recent filings

Filing Released Lang Actions
FORM 8K
Regulatory Filings
2025-11-07 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or disclosures by a company. The text specifically mentions Item 7.01 Regulation FD Disclosure and includes a company presentation as Exhibit 99.1. The document does not contain detailed financial statements or comprehensive financial analysis but rather announces the availability of a presentation on the company's website and attaches it. The length is 6672 characters, which is relatively short and consistent with an announcement rather than a full report. The nature of the content is a disclosure of a presentation, which fits the category of Investor Presentation (IP). Therefore, the filing type is Investor Presentation (IP).
2025-10-14 English
424B3
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) under the Securities Act, related to the resale of common shares by selling stockholders. It includes detailed information about the offering, risk factors, use of proceeds, description of capital stock, and a recent merger transaction. The document is a registration and offering prospectus, which is a type of capital raising document. It is not a financial report, earnings release, management discussion, or any other report type. It is clearly related to capital/financing activities, specifically a resale offering of shares by selling stockholders. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus, not just an announcement or a brief summary.
2025-09-29 English
Regulatory Filings 2025
Regulatory Filings
2025-09-25 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the U.S. Securities and Exchange Commission requesting acceleration of the effective date of a Registration Statement on Form S-3. It is a formal correspondence related to a securities registration process, not a financial report or detailed filing. The document length is short (1538 characters), and it does not contain financial data or detailed report content. It is essentially a regulatory communication about the registration statement's effective date, which fits best under Regulatory Filings (RNS) as a general regulatory announcement and correspondence with the SEC.
2025-09-24 English
S-3/A
Regulatory Filings Classification · 95% confidence The document is a Form S-3/A, which is an amendment to a registration statement filed under the Securities Act of 1933. It includes details about the registration of securities, indemnification of officers and directors, and other regulatory disclosures. The document is not a financial report like an annual or quarterly report, nor is it an earnings release or a call transcript. It is a regulatory filing related to securities registration and compliance with SEC rules. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a proxy statement but a detailed regulatory filing.
2025-09-19 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.